🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the infection, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million new cases per year. Notably increased rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This approval signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

As per results published in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The trial included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to make available and distribute the drug in many regions with limited resources.

Medical professionals directly involved have expressed hope. Having a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.